CASE REPORTS CASE REPORT
A 32-year-old man who was previously healthy had a 1-week history of increasing abdominal pain, nausea, and distention. A physical examination was significant for abdominal distension without tenderness, hypoactive bowel sounds, guaiac-positive stools, and normal peripheral pulses. Metabolic acidosis was not revealed by means of laboratory studies; however, the white blood cell count was elevated at 22,000 (normal, 4000 to 11,000), with a left shift. Lack of flow in the portal vein was shown by means of a Doppler ultrasound scanning examination. Portal vein, splenic vein, and diffuse superior mesenteric vein (SMV) thrombosis was demonstrated by means of an abdominal computed tomography (CT) scan. The small bowel was diffusely dilated and thickened, and a small amount of ascites was present (Fig 1) . The patient had no past personal or family history of thrombotic events. Intravenous heparin was initiated, and some melenic stools developed in the patient, who required a transfusion of 3 units of blood. The patient remained hemodynamically stable during this time.
Because of a previous report, 2 we thought that anticoagulation with heparin and concomitant superior mesenteric artery thrombolytic therapy with urokinase was the best course, with transfusion support if there was ongoing gastrointestinal (GI) bleeding. The GI bleeding was thought to be caused by diffuse mucosal ischemia and slough related to venous congestion and diffuse small bowel edema. We thought that the GI bleeding was selflimited and thrombolytic therapy should still be tried.
The patient underwent right femoral artery cannulation, and a 5F Cook catheter (Cook, Bloomington, Ind) was advanced into the superior mesenteric artery (SMA). Delayed images showed no flow in the portal, splenic, or superior mesenteric veins, with a few small splenic and periportal venous collaterals (Fig 2) . Urokinase was infused at 240,000 U/h for 2 hours, and then continued at 100,000 U/h for the next 4 days. Heparin infusion was maintained at therapeutic levels of two times the control throughout therapy. Progressive increase in portal and mesenteric flow was shown by means of daily repeated angiography (Fig 3) . The catheter was removed on the fifth day of hospitalization. There was no further GI bleeding or transfusion administered after the initiation of urokinase. On completion of the urokinase infusion, the patient was continued on heparin. Normal directional flow in the portal and splenic veins was demonstrated by means of ultrasound scanning. On day 6 of hospitalization, warfarin was initiated, and heparin was stopped when a therapeutic level was achieved.
Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery Extensive laboratory testing for a primary hypercoagulable state was performed on admission. Testing included: assay for factor V-Leiden mutation; antithrombin III and protein C and S levels; antiphospholipid antibody; anticardiolipin antibody; tests for collagen vascular disease; factor II level; plasma homocysteine level; and screen for paroxysmal nocturnal hemoglobinuria. All tests were normal (including the factor V gene), with the exception of a low protein S level, which was 54% of normal.
The patient was discharged on the ninth day of hospitalization, taking warfarin and tolerating a regular diet. At a follow-up examination 8 months later, the patient was doing well and tolerating a regular diet; he will remain on lifelong anticoagulation with warfarin.
DISCUSSION
Mesenteric venous thrombosis is a rare but lifethreatening disease. Traditional surgical treatment of this disease centered around early diagnosis and operation with resection of nonviable bowel. It is often difficult to distinguish viable and nonviable bowel because of the diffuse edema and venous congestion, and second-look procedures are frequently recommended. 1 This approach is uniformly unsatisfying and associated with high mortality (30% to 50%) and recurrence rates (10% to 30%). 1 Thrombolytic therapy for mesenteric venous thrombosis is a novel alternative treatment approach that may allow surgery to be reserved for patients with the complication of bowel infarction with peritonitis or patients who can-not receive thrombolytics. Historically, the standard approach to a patient with SMV thrombosis and ascites would be operative exploration. We thought that this patient was hemodynamically stable, without the presence of metabolic acidosis or significant abdominal tenderness, and would be a good candidate for nonoperative treatment with thrombolytics. The ascites noted by means of the abdominal CT scan was felt to be a result of acute portal venous hypertension and diffuse bowel edema and not an indicator of bowel injury requiring operation. The GI bleeding was thought to be an initial self-limited event related to mucosal slough and was not considered to be an absolute contraindication to thrombolytic therapy.
Superior mesenteric artery urokinase infusion avoids the risks of a transhepatic approach. Our report extends the time of infusion to 96 hours without complications. The duration of thrombolytic therapy can be variable, but complications increase with the length of time of infusion. 4 Although there was still a small amount of residual thrombus after 96 hours of urokinase infusion, the acute portal venous hypertension had been reversed, and the patient was clinically improved. There is no established guideline other than clinical judgment for the end point of thrombolytic therapy at this time.
Risk factors for venous thrombosis include hypercoagulable states, portal hypertension, trauma, postsplenectomy, malignancy, inflammatory states, pregnancy, and oral contraceptive use. [6] [7] [8] [9] In young patients who do not have known risk factors for thrombosis, a thorough workup for a primary hypercoagulable state is warranted. Overall, the most common cause is myeloproliferative disease. Other causes include genetic factors such as: factor V Leiden mutation (activated protein C resistance); antithrombin III deficiency; protein C or S deficiency or resistance; factor II deficiency; plasma hyperhomocystinemia; paroxysmal nocturnal hemoglobinuria; or acquired risk factors such as antiphospholipid antibody or anticardiolipin antibody syndromes, collagen vascular disease, or dysfibrinogenemia. [6] [7] [8] [9] Therapy is tailored to the specific disorder; however, when a significant thrombotic event occurs, lifelong anticoagulation with warfarin is usually necessary.
Genetic factors have recently been recognized as important causes of venous thrombosis. The factor V Leiden mutation is the most common cause of inherited venous thrombosis (usually lower-extremity deep venous thrombosis). Protein S is a plasma protein that acts as a co-factor to protein C, which inhibits coagulation by proteolytically inactivating factors V and VIII. 6 Protein S deficiency is rare, accounting for less than 5% of the inherited thrombotic disorders, and is almost exclusively associated with venous, rather than arterial, thrombosis. In 39% of patients who are protein S deficient and who have a thrombotic event, there is an associated genetic risk factor of the factor V Leiden mutation. 7 Because this patient had known protein S deficiency, heparin was continued during the initiation of warfarin anticoagulation to avoid complications related to an initial paradoxical hypercoagulable state (warfarin-induced skin necrosis). Only after achieving a therapeutic prothrombin with warfarin was the heparin discontinued. 
